1. Home
  2. NCEL vs CURX Comparison

NCEL vs CURX Comparison

Compare NCEL & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$2.69

Market Cap

13.2M

Sector

Health Care

ML Signal

N/A

CURX

Curanex Pharmaceuticals Inc

N/A

Current Price

$0.42

Market Cap

11.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCEL
CURX
Founded
2008
2018
Country
Switzerland
United States
Employees
11
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
11.6M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
NCEL
CURX
Price
$2.69
$0.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.2K
5.3M
Earning Date
04-10-2026
09-09-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.89
$0.26
52 Week High
$4.70
$9.18

Technical Indicators

Market Signals
Indicator
NCEL
CURX
Relative Strength Index (RSI) 36.99 56.19
Support Level $2.44 $0.37
Resistance Level $3.16 $0.51
Average True Range (ATR) 0.16 0.05
MACD -0.03 0.00
Stochastic Oscillator 0.00 44.12

Price Performance

Historical Comparison
NCEL
CURX

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.

About CURX Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.

Share on Social Networks: